Financial Data

Starting from the fiscal year ended March 31, 2018 the Group has adopted IFRS.
Figures for the fiscal year ended March 31, 2017 are shown under IFRS in addition to under JGAAP.

Financial Highlights (Consolidated)

  • Revenue

    Revenue

  • Operating profit

    Operating income

  • Core operating profit (IFRS)

    Core operating profit (IFRS)

    ※Core operating profit is calculated by deducting from operating profit any gains and losses resulting from nonrecurring factors that the Group designates.

  • Ordinary income (JGAAP)

    Ordinary income

  • Profit attributable to owners of the parent

    Profit attributable to owners of the parent

  • R&D expenses

    R&D expenses

  • Capital expenditures

    Capital expenditures

  • Depreciation and amortization

    Depreciation and amortization

  • Total assets

    Total assets

  • Equity

    Equity

Cash Flows

Cash Flows

  • Earnings per share

    Earnings per share

  • Equity per share

    Equity per share

  • Cash dividends applicable to the year

    Cash dividends applicable to
the year

  • Operating profit to sales

    Operating profit to sales

  • Core operating profit to sales

    Core operating profit to sales

  • Profit / Equity attributable to owners of parent (ROE)

    Profit / Equity attributable to owners of parent (ROE)

  • Equity ratio

    Equity ratio

Revenue ratio of each business segment

Revenue ratio of each business segment

(millions of yen)

JGAAP IFRS
Year ended March 31,2016 Year ended March 31,2017 Year ended March 31,2017 Year ended March 31,2018
Fiscal Year
Revenue 403,206 411,639 408,357 466,838
Operating profit 36,929 52,501 40,286 88,173
Core operating profit - - 64,372 90,604
Ordinary income 35,221 54,083 - -
Profit attributable to owners of the parent 24,697 28,733 31,316 53,448
R&D expenses 82,033 80,819 81,373 86,928
Capital expenditures 7,364 6,680 7,835 10,201
Depreciation and amortization 14,286 13,058 12,713 12,887
End of Fiscal Year
Total assets 707,715 783,640 779,072 809,684
Equity 446,472 460,389 412,268 452,723
Cash Flows
Net cash provided by operating activities 49,415 21,624 19,143 93,420
Net cash used in investing activities 15,887 -59,729 -56,129 -16,523
Net cash used in financing activities -42,605 9,881 8,764 -29,610

(yen)

JGAAP IFRS
Year ended March 31,2016 Year ended March 31,2017 Year ended March 31,2017 Year ended March 31,2018
Amount per share
Earnings per share 62.16 72.32 78.82 134.53
Equity per share 1,123.76 1,158.80 1,037.68 1,139.50
Cash dividends applicable to the year 18 20 20 28 (forecast)
Financial index
Operating profit to sales 9.2% 12.8% 9.9% 18.9%
Core operating profit to sales - - 15.8% 19.4%
Profit / Equity attributable to owners of parent (ROE) 5.5% 6.3% 7.8% 12.4%
Equity ratio 63.1% 58.8% 52.9% 55.9%
Revenue ratio of each business segment
Pharmaceuticals 89.5% 89.4% 89.3% 90.8%
Other products 10.5% 10.6% 10.7% 9.2%